Page last updated: 2024-12-04

2-(3-pyridine)acetic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-(3-pyridine)acetic acid, also known as **nicotinic acid**, is a **heterocyclic carboxylic acid**. It's crucial to understand that it's **not** the same thing as 2-(3-pyridine)acetic acid, which is a completely different molecule.

Here's a breakdown:

**1. Nicotinic Acid (Niacin):**

* **Structure:** Nicotinic acid is a pyridine derivative with a carboxylic acid group attached to the 3-position of the pyridine ring.
* **Importance in Research:**
* **Vitamin B3:** Nicotinic acid is a vital B vitamin, essential for various metabolic processes, including energy production (Krebs cycle), DNA repair, and cellular signaling.
* **Treating Pellagra:** Nicotinic acid deficiency leads to the disease pellagra, characterized by skin lesions, diarrhea, and dementia.
* **Cardiovascular Health:** Nicotinic acid has been investigated for its potential to lower cholesterol levels and improve cardiovascular health.
* **Other Research Areas:** Nicotinic acid is also being explored for its potential benefits in treating other conditions like Alzheimer's disease, diabetes, and inflammation.

**2. 2-(3-Pyridine)acetic Acid:**

* **Structure:** This molecule would have a pyridine ring with a methyl group (CH3) attached to the 3-position and a carboxylic acid group (COOH) attached to the 2-position.
* **Importance in Research:**
* **Limited Information:** There is limited information available about the specific research applications of this particular compound. It's possible that it could be used as a building block for synthesizing other molecules with pharmacological properties.
* **Potential for Research:** The structure suggests the possibility of biological activity, but further research is needed to explore its potential applications.

**To summarize:**

* Nicotinic acid (vitamin B3) is a well-known and important compound with established roles in health and research.
* 2-(3-pyridine)acetic acid is a less-studied molecule, and its research significance is still being explored.

If you have more information about 2-(3-pyridine)acetic acid, such as its specific properties or potential use, I can provide more details.

3-pyridylacetic acid : A monocarboxylic acid that is acetic acid substituted by a (pyridin-3-yl) group. It is a metabolite of nicotine and other tobacco alkaloids. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID108
CHEMBL ID1741437
CHEBI ID86390
SCHEMBL ID48609
MeSH IDM0547311

Synonyms (87)

Synonym
BB 0259224
gtpl1590
3-pyridine-acetic acid
NCI60_038230
piristerol
NSC70769 ,
nsc-70769
501-81-5
3-pyridinylacetic acid
lessterol
piridil
minedil
3-pyridineacetic acid
2-(3-pyridyl)acetic acid
coletin
3-pyridylacetate
lioxone
pyridine-3-acetic acid
3-pyridylacetic acid
toneon
NCGC00013785
pyridin-3-ylacetic acid
inchi=1/c7h7no2/c9-7(10)4-6-2-1-3-8-5-6/h1-3,5h,4h2,(h,9,10
EU-0033240
NCI70769
NCISTRUC1_001832
NCISTRUC2_000005
OPREA1_245722
NCGC00096895-01
AKOS000200472
HMS1648N01
homonicotinic acid
2-pyridin-3-ylacetic acid
A8810
A7443
BBL001481
STL102634
CHEMBL1741437
chebi:86390 ,
2-(pyridin-3-yl)acetic acid
3-pyridylaceticacid
3-pyridylaceticacidhydrochloride
EN300-53587
unii-7ufo07435n
7ufo07435n ,
nsc 70769
einecs 207-928-7
CCG-37668
NCGC00013785-02
FT-0674203
FT-0601403
AM20070145
3paa
.alpha.-(3-pyridyl)acetic acid
risedronate sodium impurity, 3-pyridyl acetic acid-[usp impurity]
risedronate sodium 2.5-hydrate impurity d [ep impurity]
3-pyridyl acetic acid
3-pyridineacetic acid [mi]
SCHEMBL48609
(pyridin-3-yl)acetic acid
3-pyridine acetic acid
3-pyridyl-acetic acid
(3-pyridyl)ethanoic acid
pyridin-3-yl-acetic acid
FG-0453
DTXSID3060110
3-pyridinylacetic acid #
DS-0484
AC-24998
3-pyridineacetic acid,sodium salt(1:1)
F8880-7238
J-506582
J-800109
a-(3-pyridyl)acetic acid
2-(3-pyridyl)acetate
a-(3-pyridyl)acetate
alpha-(3-pyridyl)acetic acid
3-carboxymethylpyridine
2-(pyridin-3-yl)acetate
HY-W015806
CS-W016522
3-pyridilacetic acid
BCP20278
mfcd00066302
Q27073746
alpha-(3-pyridyl)acetate
Z285131558
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyridinesAny organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives.
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nicotinate phosphoribosyltransferaseHomo sapiens (human)Ki0.00130.00000.00060.0019AID1618606
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
response to oxidative stressNicotinate phosphoribosyltransferaseHomo sapiens (human)
NAD salvageNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nicotinate phosphoribosyltransferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
protein bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
transferase activityNicotinate phosphoribosyltransferaseHomo sapiens (human)
metal ion bindingNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
extracellular regionNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
azurophil granule lumenNicotinate phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeNicotinate phosphoribosyltransferaseHomo sapiens (human)
cytosolNicotinate phosphoribosyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID605760Inhibition of Escherichia coli recombinant DXR using DXP as substrate and MgCl2 as cofactor preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID605841Inhibition of Mycobacterium tuberculosis recombinant DXR expressed in Escherichia coli BL21 (DE3) using DXP as substrate and MgCl2 as cofactor at 100 uM preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID605761Inhibition of Escherichia coli recombinant DXR using DXP as substrate and MgCl2 as cofactor at 100 uM preincubated for 10 mins2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies.
AID1346416Human HCA2 receptor (Hydroxycarboxylic acid receptors)2003The Journal of biological chemistry, Mar-14, Volume: 278, Issue:11
Molecular identification of high and low affinity receptors for nicotinic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.84 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]